Syndax Pharmaceuticals, Inc. Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31)
Syndax Pharmaceuticals, Inc. (SNDX) reported Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) of 2.02% for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssumptionsRiskFreeInterestRate · last filed 2018-03-08
- Syndax Pharmaceuticals, Inc. fair value assumptions, risk free interest rate (deprecated 2018-01-31) for fiscal 2017 was 2.02%, a 43.26% increase from fiscal 2016.
- Syndax Pharmaceuticals, Inc. fair value assumptions, risk free interest rate (deprecated 2018-01-31) for fiscal 2016 was 1.41%, a 18.50% decline from fiscal 2015.
- Syndax Pharmaceuticals, Inc. fair value assumptions, risk free interest rate (deprecated 2018-01-31) for fiscal 2015 was 1.73%, a 9.42% decline from fiscal 2014.
- Syndax Pharmaceuticals, Inc. fair value assumptions, risk free interest rate (deprecated 2018-01-31) for fiscal 2014 was 1.91%.
| Period end | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 12 month |
|---|---|
| 2017-12-31 | 2.02% 10-K · filed 2018-03-08 |
| 2016-12-31 | 1.41% 10-K · filed 2018-03-08 |
| 2015-12-31 | 1.73% 10-K · filed 2018-03-08 |
| 2014-12-31 | 1.91% 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |